

Standardising definitions for the pre-eclampsia core outcome set:

A consensus development study

James M. N. Duffy ^{a,b}, Alexandra E. Cairns ^a, Laura A. Magee ^c, Peter von Dadelszen ^c,
Janneke van 't Hooft ^d, Chris Gale ^e, Mark Brown ^f, Lucy C. Chappell ^c, William A. Grobman ^g,
Ray Fitzpatrick ^h, S. Ananth Karumanchi ⁱ, D. Nuala Lucas ^j, Ben Mol ^k, Michael Stark ^l,
Shakila Thangaratinam ^m, Mathew J. Wilson ⁿ, Paula R. Williamson ^o, Sue Ziebland ^a,
Richard J. McManus ^a and the International Collaboration to Harmonise Outcomes for Pre-
eclampsia (iHOPE)

^a Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

^b Institute for Women's Health, University College London, London, United Kingdom.

^c Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, United Kingdom.

^d Department of Obstetrics and Gynecology, Amsterdam UMC, Academic Medical Center, Amsterdam, Netherlands.

^e Academic Neonatal Medicine, Imperial College London, London, United Kingdom.

^f Department of Renal Medicine, St George Hospital and University of New South Wales, Kogarah, Australia.

^g Department of Obstetrics and Gynaecology, Feinberg School of Medicine, Northwestern University, Chicago, United States.

^h Health Services Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

ⁱ Cedars-Sinai Medical Center, Los Angeles, California, United States.

^j London North West University Healthcare NHS Trust, Harrow, United Kingdom.

^k Women's Health Care Research Group, Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia.

^l Department of Obstetrics and Gynaecology, University of Adelaide, Adelaide, Australia.

^m Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, London, United Kingdom.

ⁿ School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.

^o MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.

Correspondence to:

Dr James M. N. Duffy DPhil MRes PG HCL MBChB BSc (Hons)
Institute for Women's Health, University College London
84-86 Chenies Mews, London WC1E 6HU
United Kingdom
+44 (0)7949 066806
james.duffy3@nhs.net

Short title

Standardising definitions for pre-eclampsia research

Funding sources

This study was funded by the Barts Charity, Elisabeth Garrett Anderson Hospital Charity, and National Institute for Health Research. The funders have no role in the design and conduct of the study, the collection, management, analysis, or interpretation of data, or manuscript preparation.

Declaration of interest

Dr Gale has received expenses to attend an educational conference from Chiesi Pharmaceuticals and his institution has received research funding from Chiesi Pharmaceuticals. Prof Karumanchi reports serving as a consultant to Roche and Thermofisher Scientific and has a financial interest in Aggamin Pharmaceuticals. Prof Mol is a consultant for ObsEva. The remaining authors declare no competing interests.

Objectives

To develop consensus definitions for the core outcome set for pre-eclampsia.

Study design

Potential definitions for individual core outcomes were identified across four formal definition development initiatives, nine national and international guidelines, 12 Cochrane systematic reviews, and 79 randomised trials. Eighty-six definitions were entered into the consensus development meeting. Ten healthcare professionals and three researchers, including six participants who had experience of conducting research in low- and middle-income countries, participated in the consensus development process.

Results

Consensus definitions were developed for all core outcomes. When considering stroke, pulmonary oedema, acute kidney injury, raised liver enzymes, low platelets, birth weight, and neonatal seizures, consensus definitions were developed specifically for low- and middle-income countries because of the limited availability of diagnostic interventions including computerised tomography, chest x-ray, laboratory tests, equipment, and electroencephalogram monitoring.

Conclusions

Consensus on measurements for the pre-eclampsia core outcome set will help to ensure consistency across future randomised trials and systematic reviews. Such standardization should make research evidence more accessible and facilitate the translation of research into clinical practice.

Keywords

Consensus development study, core outcome set, hypertension in pregnancy, outcome measure, pre-eclampsia, and randomised controlled trials.

Insert video abstract:

www.dropbox.com/s/ftqgvfu0u9glqd/6.%20Standardising%20definitions%20in%20the%20pre-eclampsia%20core%20outcome%20set%3A%20a%20consensus%20development%20study.mp4?dl=0

Introduction

Randomised trials evaluating potential treatments for pre-eclampsia have reported many different outcomes.[1-3] Variation in outcome reporting exists across many different healthcare conditions, including endometriosis, selective fetal growth restriction, and neonatal care.[4-6] This variation exists because of a failure to take into account the perspectives of women when selecting outcomes, variations in outcome definitions, and the selective reporting of outcomes based on statistical significance. Problems with poor outcome selection, measurement, and reporting can be addressed by developing, disseminating, and implementing core outcome sets.[7]

A core outcome set for randomised trial evaluating treatments following the development of pre-eclampsia has been established to standardise outcome selection, collection, and reporting across future pre-eclampsia research (Figure 1). The core outcome set was developed in a three stage process using consensus science methods advocated by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative.[8, 9] In summary, potential core outcomes were identified by developing an inventory of outcomes reported in pre-eclampsia trials and by undertaking a thematic analysis of interviews with women with lived experience of pre-eclampsia.[1, 10, 11] The long list of potential core outcomes was entered into a modified Delphi method which identified consensus outcomes. These outcomes were subsequently entered into a face-to-face consensus development meeting. Using a modified Nominal Group Technique, consensus outcomes were further prioritized to identify the final core outcome set (Table 1).[12]

Different definitions exist for individual core outcomes. For example, stillbirth has previously been defined using six different combinations of gestational ages, birth weights, and crown-heel heights.[13] Such variation makes it difficult to synthesise the results of individual trials within secondary research, including pairwise, individual patient data, and network meta-

analysis.[14] Standardising definitions for individual core outcomes presents an opportunity to develop additional harmony in future pre-eclampsia research.

In this study, we used formal consensus development methods to generate agreement on definitions for the core outcome set for pre-eclampsia.

Methods

An international steering group, including health care professionals, researchers, and women with lived experience of pre-eclampsia, was established to provide a perspective to inform key methodological decisions and to approve the final core outcome set. The protocol and other methodological decisions were informed by COMET initiative recommendations, a systematic review of registered, ongoing, and completed core outcome sets, and the steering group's experience of developing core outcome sets in other areas. [8, 9, 12, 15-26]

Potential definitions were sourced from formal definition development initiatives, national and international guidelines, Cochrane reviews, and randomised trials (Figure 2). Specific methods have been published elsewhere [8], briefly:

- A systematic review was undertaken searching the Core Outcome Measures in Effectiveness Trials initiative register to identify definition development initiatives relevant to pregnancy and childbirth research from inception to January 2017.[12]
- A systematic review of national and international pre-eclampsia guidelines was used to source definitions used within these guidelines.[27]
- Cochrane systematic reviews evaluating potential treatments for pre-eclampsia were identified by searching the Cochrane Database of Systematic Reviews from inception to August 2017, again aiming to identify standardised definitions.
- Randomised trials evaluating potential treatments for pre-eclampsia where outcomes may have been defined were identified by searching bibliographical databases, including

the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE, from inception to January 2016.[1]

From these different sources, an inventory of potential definitions was developed.[28]

A face-to-face consensus meeting is recommended by the COMET initiative and has been used by other core outcome set developers.[9] The setting in which the face-to-face consensus meeting takes is known to affect the interaction of participants, and can ultimately impact the quality of the decision making.[29] Outside the context of core outcome set development, there is limited experience of delivering formal consensus methods using teleconferencing formats which would overcome resource limitations and geographical barriers. Following careful consideration, a face-to-face consensus meeting was considered the optimal approach.

Healthcare professionals and researchers who had participated in the Delphi survey were invited to participate in a face-to-face consensus development meeting.[8] Resource limitations prevented the reimbursement of international travel and subsistence expenses and participation was limited to the United Kingdom. There is no robust method for calculating the required number of participants.[29] Following consultation with the study's steering group, we aimed to recruit between ten and 15 participants.

Before the meeting, participants provided demographic details. The consensus development meeting was moderated by an experienced and trained facilitator, Prof. Richard McManus. Each core outcome was discussed in turn. Potential definitions were displayed within the definition hierarchy. Participants were encouraged to voice their opinions on previously used definitions, to suggest new definitions if necessary, and to reformulate individual definitions to improve clarity or comprehension. Although the group was encouraged to reach consensus, members were able to express minority or alternative views when consensus could not be achieved.

The study's steering group approved the final consensus definitions. They were also able to provide feedback to improve clarity.

This study is complementary to the work of the International Society for the Study of Hypertension in Pregnancy (ISSHP) and the Global Pregnancy Collaboration who are engaged with the standardisation of study design, the development of a standardised database for perinatal research studies, and the development of clinical practice guidelines. [30, 31]

Results

Eighty-six potential outcome definitions were drawn from four definition development initiatives (Appendix S1), nine national and international clinical practice guidelines, 12 Cochrane systematic reviews, and 79 pre-eclampsia trials [1]. Thirteen participants participated in the consensus development meeting (Table 2) comprising ten healthcare professionals and three researchers. Six had experience of working in or conducting research in low- and middle-income countries.

Participants agreed maternal core outcomes should be collected up to 42 days following delivery. Offspring core outcomes should be collected for the first 28 days of life. If a baby is born prematurely, outcomes should be collected up to 28 days beyond the estimated due date.

Maternal core outcomes

Maternal mortality: Participants noted consistency across definitions in terms of a limit of 42 days after delivery, inclusion of pregnancy termination or miscarriage, and a historical limit based upon the approximate timing of first menstrual period in non-lactating women.[32] Participants discussed the possibility of extending the definition by including deaths

attributable to complications of pre-eclampsia later than 42 days; however, concerns were expressed regarding the feasibility of undertaking longer follow-up in low- and middle-income countries (Table 3).

Eclampsia: Participants identified inconsistencies in terminology across different definitions of eclampsia. A unanimous decision was made to define eclampsia as “the onset of convulsions in a woman with pre-eclampsia not attributable to other causes”. Participants discussed the importance of acknowledging the various terminology used in different settings related to convulsions including fits, generalised convulsions, tonic-clonic seizure, and seizure.

Stroke: Participants recognised pre-eclampsia as an important risk factor for both ischemic and hemorrhagic stroke.[33] Discussion focused upon the challenges of obtaining computerised tomography or magnetic resonance imaging in low- and middle-income countries, and as such separate definitions were agreed for high-income countries and low- and middle-income countries.

Cortical blindness: In the single potential definition identified, participants noted the requirement to measure visual acuity and the challenges of doing so. Such measurement is not a core competency for healthcare professionals in maternity settings, and the necessary equipment to measure visual acuity is often not readily available. Participants concluded a patient-reported symptom of visual impairment would be comparable and negate the requirement to undertake visual acuity measurement.

Retinal detachment: Participants appreciated the simplicity of the World Health Organization’s definition: “*a condition in which the retina peels away from its underlying layer of support tissue.*”[34] However, the importance of undertaking an ophthalmological

examination to confirm the diagnosis was discussed and considered essential in securing a robust diagnosis.

Pulmonary oedema: Participants agreed the clinical signs of pulmonary oedema are relatively straightforward to elicit during respiratory system auscultation. The discussion focused upon chest x-ray confirmation, with concerns expressed regarding the availability of X-ray facilities in low- and middle-income countries. Participants therefore agreed to include the requirement for an oxygen saturation below 95% and diuretic treatment when a chest x-ray is unavailable.

Acute kidney injury: Participants noted a diverse range of different definitions of acute kidney injury. A pragmatic decision was made to implement the National Institute for Health and Care Excellence standardised definition which shares a common definition with other recent national and international initiatives, including Risk, Injury, Failure, Loss, End-stage (RIFLE) renal disease, Acute Kidney Injury Network, and Kidney Disease: Improving Global Outcomes. [35-38] The discussion focused upon the measurement of creatinine during routine antenatal care. A baseline creatinine is not routinely measured in lower risk women and may not have been measured before pregnancy.[39] Therefore, an additional criterion was added to the consensus definition: serum creatinine >150 µmol/L (> 1.6 mg/dl) in the absence of a baseline serum creatinine. A lower threshold was thought not to be sufficiently discriminatory in the absence of a baseline measurement. It was noted that the inclusion of oliguria within the definition would assist with securing the relevance of the definition within low- and middle-income countries where the measurement of serum creatinine was not consistently available.

Liver capsule haematoma: Participants unanimously recommended the definition previously reported in randomised trials adopted from the prediction of adverse maternal outcomes in pre-eclampsia study.[40]

Placental abruption: Participants unanimously agreed the definition developed as part of the Brighton Collaboration case definition study.[41]

Postpartum haemorrhage: Participants discussed the challenges of defining postpartum haemorrhage when considering the contribution of the mode of delivery, estimating blood loss, and differences in thresholds when further medical or surgical intervention to manage postpartum haemorrhage is deemed necessary. Participants agreed a common starting point is the recognition of heavy abnormal bleeding following childbirth. A specific volume threshold was considered unhelpful as there is marked inter-observer variability in estimating blood loss.[42] Participants discussed the importance of demonstrating hypotension and/or the use of pharmacologic or surgical interventions to manage postpartum haemorrhage as important components of the consensus definition.

Raised liver enzymes: Participants recognised that the reference ranges for liver transaminases vary both during the three trimesters of pregnancy and between different laboratories. Participants unanimously recommended the consensus definition should not state a specific threshold but that aspartate aminotransferase (AST) and alanine transaminase (ALT) should be elevated at least twice the upper limit of normal for the laboratory where the sample is tested. Participants noted the measurement of liver enzymes might not be available in all settings in low- and middle-income countries.

Low platelets: Participants discussed the different thresholds defining thrombocytopenia. In pregnancy thrombocytopenia is defined as a platelet count of less than $150 \times 10^9/L$; however, counts below $100 \times 10^9/L$ are more typical in HELLP syndrome and in severe cases, the platelet count may fall below $30 \times 10^9/L$. [43, 44] Participants agreed that platelet counts below $100 \times 10^9/L$ should be used as the threshold for the consensus definition.

Admission to intensive care unit required: Participants unanimously agreed on a consensus definition, highlighting the importance of collecting and reporting the requirement for intensive care unit admission even if women are unable to be admitted to an intensive care unit because of logistics or availability of such services. The lack of unit capacity will be particularly relevant to research conducted in low- and middle-income countries.[45]

Intubation and mechanical ventilation not for purposes of operative delivery: Participants unanimously agreed on a consensus definition.

Offspring core outcomes

Stillbirth: Participants reviewed the different definitions which incorporated different quantifiable parameters, including clinical estimates of gestational age, birth weight, and crown-heel height.[46] Participants highlighted the World Health Organization's definition for stillbirth is the most widely used.[47] The inclusion of height and weight thresholds secures its feasibility in low- and middle-income countries.[47] Consensus was reached to select the World Health Organization's definition.[34]

Gestational age at delivery: Participants considered gestational age at delivery as a well-characterised outcome with an internationally accepted definition.[48] There was unanimous agreement to adopt this definition.

Birth weight: Participants agreed birth weight should be collected within 24 hours of birth.[48] Participants noted best practice recommendations regarding the measurement of birth weight should be adhered to in future pre-eclampsia research including weight assessed using a calibrated electronic scale with 10-gram resolution.[48] Participants noted that in low- and middle-income countries calibrated electronic scales may not be readily available, and the calibration and type of scale should be clearly reported. Participants recommended birth weight should be reported separately for each infant in a multi-fetal pregnancy.

321

322 Small for gestational age infants: Participants discussed the importance of assessing small
 323 for gestational age using validated growth charts. A variety of different international, regional,
 324 and local growth charts are available.[49] Participants unanimously agreed a 10th percentile
 325 threshold was appropriate to identify small for gestational age newborn infants and any
 326 validated international, regional, or local customised growth chart could be used.
 327 Researchers should clearly report the customised growth chart they used. Participants
 328 agreed small for gestational age infants should be reported for all births, including stillbirths.

329

330 Neonatal mortality: Participants noted the consistent use of the World Health Organization
 331 definition for neonatal mortality, “*deaths among live births during the first 28 completed days*
 332 *of life*”, across definition development initiatives, international and national guidelines,
 333 Cochrane systematic reviews, and randomised controlled trials.[34] When considering
 334 preterm infants, neonatal mortality should be reported if death occurs within 28 days of the
 335 estimated due date.

336

337 Neonatal seizures: Participants noted World Health Organization guidelines described the
 338 most practical method of diagnosing neonatal seizures, based upon clinical recognition.[50]
 339 Neonatal seizures commonly present with focal clonic movements; however, they can
 340 present with more subtle signs which can be easily misinterpreted as either crying or cycling
 341 movements of the limbs.[50] Electroencephalogram (EEG) monitoring can support the
 342 diagnosis. However, its availability in low- and middle-income countries is limited.
 343 Participants agreed a common starting point is the recognition of neonatal seizures.
 344 Separate definitions were agreed for high-income countries and low- and middle-income
 345 countries.

346

347 Respiratory support: Participants agreed on a consensus definition which included
 348 continuous positive airway pressure, non-invasive positive pressure ventilation, or intubation

and mechanical ventilation. When considering low- and middle- income countries specifically, headbox oxygen and nasal cannula oxygen would be included within the definition. Participants discussed the inclusion of supplemental oxygen; however, concerns were expressed that this would represent an overly inclusive definition as supplemental oxygen is a commonly used non-specific intervention.[51]

Admission to a neonatal unit required: Participants discussed the lack of consensus regarding the local, regional, or national criteria used to assess the need for admission to a special care baby unit or neonatal intensive care unit.[52] Consensus was reached to recommend a broad definition to recognise this variation in admission criteria. The definition highlights the importance of collecting and reporting the requirement for admission to a special care baby unit or neonatal intensive care unit even if the neonate cannot be admitted. The lack of capacity will be particularly relevant to research conducted in low- and middle-income countries.[53]

Disucssion

Using formal consensus methods, healthcare professionals and researchers have developed standardised definitions for the core outcome set for pre-eclampsia. For stroke, pulmonary oedema, acute kidney injury, raised liver enzymes, low platelets, birth weight, and neonatal seizures, consensus definitions were developed specifically for low- and middle-income countries because of the limited availability of diagnostic interventions including chest x-ray, laboratory tests, and equipment (Table 3). Such modification ensures the core outcome set can be feasibly collected in low- and middle-income countries. The consensus definition for maternal admission to intensive care and admission to a neonatal unit emphasised the requirement for admission, to address potential lack capacity which can occur in all settings.

This study has completed our overall objective of producing a core outcome set aiming to standardise future pre-eclampsia trials and systematic reviews by identifying what outcomes

to measure, when they should be measured, and how they should be measured. A comprehensive inventory of potential definitions was developed by a diverse range of researchers and healthcare professionals resulting in clear definitions which could be used to collect core outcomes across different settings.

This study is not without limitations. Participants in the consensus meeting currently live in the United Kingdom, although six participants (46%) had lived, worked, or conducted research in a low- and middle-income country. This could have impacted on the generalisability of the consensus definitions prioritised but was a pragmatic choice in the light of limited resources which precluded inclusion of international participants. Use of the core outcome set in a variety of countries will ascertain the extent to which this is an issue and definitions may need further adjustment.

The consensus development meeting did not include women with lived experience of pre-eclampsia because the anticipated discussion would involve the technical details of outcome definition and collection. Once a consensus definition was formally agreed, participants had the opportunity to comment further. The study design could have incorporated formal and anonymous voting to assess the level of agreement for individual consensus definitions. Further methodological research is required to develop an appropriate definition of consensus in exercises similar to ours.

Having established consensus definitions, researchers should use them, and guideline developers should build their clinical practice guidelines around them. However, consensus definitions are not meant to prevent the use of other appropriate definitions in specific circumstances. For example, researchers undertaking research in Australia may wish to define stillbirth as occurring after 20 weeks of gestation in line with local Epidemiology and Surveillance Branch recommendations.[13] Researchers wishing to collect data using other definitions in the context of their own randomised trial would continue to be able to do so.

However, selective reporting should be avoided by presenting findings for both the consensus definition and any other definition used. The consensus definitions should always be the primary definition collected and reported. Researchers would need to carefully consider how these data would be collected to fulfil different definitions. In the example of a stillbirth, the common components of all definitions, including gestational age, birth weight, and crown-heel height, should be recorded separately and combined to fulfil the consensus definition (gestational age, birth weight, and crown-heel height) and the Australian definition (gestational age and birth weight).

Consensus definitions should prevent misclassifications and reduce measurement error.[54] Such standardisation ensures the consensus definitions can be applied symmetrically to the trial arms, avoiding bias in the measurements. Several consensus definitions, including abruption, postpartum haemorrhage, and neonatal seizures, require professional assessment. Any assessment should be determined by an observer with comprehensive training. Differential and biased misclassification of outcomes can occur in poorly designed randomised trials. For example, for postpartum haemorrhage: outcome assessors may perform laboratory investigations more regularly in participants allocated to the experimental treatment when compared to the control. Systematic evaluations of observer bias have demonstrated non-masked outcome assessors consistently over diagnose clinical outcomes when compared with masked outcome assessors.[55] Several strategies exist to increase the likelihood of standardised definitions being applied to accurately classify clinical outcomes, including standardised data collection tools, validation studies, and independent adjudication panels. This would increase the likelihood that core outcomes are classified accurately and without variation.[56]

The Core Outcomes in Women's and Newborn Health (CROWN) initiative, supported by over 80 specialty journals, including *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*, have resolved to implement the core outcome set for pre-

eclampsia.[12] Participating journals will require researchers to report the definition for individual core outcomes within randomised trial and systematic review reports. When the consensus definition has not been used, the researchers will be asked to report their definition.

Successful implementation should help to enable the coordination and planning of pre-eclampsia research within a regional, national, and international context.[57] Other initiatives, including the development of research priorities, standardising the definition of hypertension disorders in pregnancy, and standardised data collection tools could support national and international co-operation.[58] Ensuring core outcomes are consistently defined across future randomised controlled trials and systematic reviews, will secure evidence which is more accessible and facilitate the translation of research into clinical practice.[59, 60] It is hoped the core outcome set will ultimately improve the outcomes of women and their babies.

International Collaboration to Harmonise Outcomes for Pre-eclampsia (iHOPE)

Dr Edgardo J. Abalos, Centro Rosarino de Estudios Perinatales, Argentina; Christine C. D. Adamson, Chelsea and Westminster Hospital NHS Foundation Trust, United Kingdom; Dr Adebayo A. Akadri, Babcock University, Nigeria; Professor Zekeriya Akturk, Ailem Academic Counselling, Turkey; Professor Karel Allegaert, KU Leuven, Belgium; Dr Edith Angel-Müller, Universidad Nacional de Colombia, Colombia; Jessica Antretter, Northwell Health, United States; Dr Helen F. Ashdown, University of Oxford, United Kingdom; Professor Francois Audibert, Université de Montréal, Canada; Dr Nathalie Auger, University of Montreal Hospital Centre, Canada; Professor Canan Aygun, Ondokuz Mayıs University, Turkey; Dr Inas Babic, Prince Sultan Military Medical City, Saudi Arabia; Professor Rashmi Bagga, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Judith M. Baker, South Africa; Dr Pradipta Bhakta, University Hospital Limerick, Ireland; Professor Vineet Bhandari, Drexel University, United States; Dr Sohinee Bhattacharya, University of Aberdeen, United

461 Kingdom; Dr Marco H. Blanker, University of Groningen, The Netherlands; Professor Frank
 462 H. Bloomfield, University of Auckland, New Zealand; Dr Anna Bof, Australia; Siobhan M.
 463 Brennan, Ireland; Dr Kim Broekhuijsen, Haaglanden Medisch Centrum, The Netherlands;
 464 Professor Emeritus Fiona Broughton Pipkin, Nottingham University Medical School, United
 465 Kingdom; Dr Joyce L. Browne, Utrecht University, The Netherlands; Dr Roger M.
 466 Browning, King Edward Memorial Hospital for Women, Australia; Jameson W. Bull, United
 467 States; Dr Amina Butt, Saudi Arabia; Dena Button, United States; Dr Jeremy P. Campbell,
 468 Imperial College Healthcare NHS Trust, United Kingdom; Dr Doris M. Campbell, University
 469 of Aberdeen, United Kingdom; Professor Lionel Carbillon, Jean-Verdier Hospital, France;
 470 Sarah Carthy, United Kingdom; Dr Emma Casely, United Kingdom; Dr James A. Cave,
 471 Downland Practice, United Kingdom; Professor Jose G. Cecatti, University of Campinas,
 472 Brazil; Dr Mónica E. Chamillard, Centro Rosarino de Estudios Perinatales, Argentina;
 473 Professor Dominique Chassard, Université Lyon, France; Dr Nancy C. Checheir, University
 474 of North Carolina School of Medicine, United States; Professor Vasilii S. Chulkov, South Ural
 475 State Medical University, Russia; Dr Catherine A. Cluver, Stellenbosch University, South
 476 Africa; Carole F. Crawford, University of Oxford, United Kingdom; Mandy C. Daly, Irish
 477 Neonatal Health Alliance, Ireland; Professor Dorota A. Darmochwal-Kolarz, University of
 478 Rzeszow, Poland; Ruth E. Davies, United Kingdom; Professor Mark W. Davies, Royal
 479 Brisbane and Women's Hospital, Australia; Dr James S. Dawson, Nottingham University
 480 Hospitals NHS Trust, United Kingdom; Nichola Dobson, United Kingdom; Claire N. Dodd,
 481 University Hospitals of Leicester, United Kingdom; Dr Fiona Donald, North Bristol NHS Trust,
 482 United Kingdom; Emeritus Professor Lelia Duley, University of Nottingham, United Kingdom;
 483 Jorie Epstein-Mares, United States; Professor Offer Erez, Soroka University Medical Center
 484 Ben Gurion University of the Negev, Israel; Dr Emma Evans, St George's University
 485 Hospitals NHS Foundation Trust, United Kingdom; Dr Richard N. Farlie, HOSPITALSENHED
 486 Midt, Denmark; Amy V. Ferris, United Kingdom; Elizabeth M. Frankland, United Kingdom; Dr
 487 Dilys J. Freeman, University of Glasgow, United Kingdom; Dr Shalini Gainer, Postgraduate
 488 Institute of Medical Education and Research, India; Dr Wessel Ganzevoort, Amsterdam

489 Universitair Medische Centra, The Netherlands; Dr Oghenekome A. Gbinigie, United
 490 Kingdom; Dr Sanjib K. Ghosh, All India Institute of Medical Sciences Patna, India; Dr
 491 Margaret Glogowska, University of Oxford, United Kingdom; Andrea Goodlife, University
 492 Hospitals of Leicester, United Kingdom; Dr Katie L. Gough, Luton and Dunstable University
 493 Hospital, United Kingdom; Jessica R. Green, United Kingdom; Professor Fouzia Gul, Khyber
 494 Medical University Institution of Medical Sciences , Pakistan; Lorraine Haggerty, Midwife Mid
 495 Essex Hospitals NHS Trust, United Kingdom; Professor David R. Hall, Stellenbosch
 496 University, South Africa; Professor Mikko Hallman, University of Oulu, Finland; Leigh M.
 497 Hamilton, New Zealand; Dr Sarah J. Hammond, St George's University Hospitals NHS
 498 Foundation Trust, United Kingdom; Professor Sloban D. Harlow, University of Michigan,
 499 United States; Dr Karen E. Hays CNM, Bastyr University, United States; Stacey C. Hickey,
 500 New Zealand; Mary Higgins, Irish Nurses and Midwives Organisation, Ireland; Dr Lisa
 501 Hinton, University of Oxford, United Kingdom; Associate Professor Sebastian R. Hobson,
 502 University of Toronto, Canada; Dr Matthew J. Hogg, Barts Health NHS Trust, United
 503 Kingdom; Heidi J. Hollands, University Hospitals Plymouth NHS Trust, United Kingdom;
 504 Professor Caroline S. E. Homer, Burnet Institute, Australia; Dr Zahra Hoodbhoy, Aga Khan
 505 University, Pakistan; Dr Paul Howell, Barts Health NHS Trust, United Kingdom; Professor
 506 Berthold Huppertz, Medical University of Graz, Austria; Dr Shahid Husain, Homerton
 507 University Hospital NHS Foundation Trust, United Kingdom; Dr Susan D. Jacoby, Mount
 508 Royal University, Canada; Professor Evelyne Jacqz-Aigrain, Université de Paris, France; Dr
 509 Gareth Jenkins, Royal Surrey County Hospital, United Kingdom; Dr David Jewel, United
 510 Kingdom; Dr Mark J. Johnson, University Hospital Southampton NHS Foundation Trust,
 511 United Kingdom; Dr Carolyn L. Johnston, St George's University Hospitals NHS Foundation
 512 Trust, United Kingdom; Paige M. Jones, United Kingdom; Professor Ira Kantrowitz-Gordon,
 513 University of Washington School of Nursing, United States; Dr Rehan-Uddin Khan, Barts
 514 Health NHS Trust, United Kingdom; Lisa J. Kirby, United Kingdom; Catherine Kirk, United
 515 Kingdom; Professor Marian Knight, University of Oxford, United Kingdom; Mary T. Korey,
 516 United States; Dr Geraint J. Lee, Evelina London Children's Hospital Neonatal Unit, United

517 Kingdom; Associate Professor Vincent W. Lee, University of Sydney, Australia; Dr Louis S.
 518 Levene, University of Leicester, United Kingdom; Dr Ambrogio P. Londero, Academic
 519 Hospital of Udine, Italy; Associate Professor Karin M. Lust, Royal Brisbane and Women's
 520 Hospital, Australia; Dr Vanessa MacKenzie, NHS Borders, United Kingdom; Dr Line Malha,
 521 Weill Cornell Medical College, United States; Dr Massimo Mattone, Italy; Dr David E.
 522 McCartney, United Kingdom; Professor Alison McFadden, University of Dundee, United
 523 Kingdom; Professor Brian H. McKinsty, University of Edinburgh, United Kingdom; Associate
 524 Professor Philippa F. Middleton, South Australian Health and Medical Research Institute,
 525 Australia; Dr Hiten D. Mistry, University of Nottingham, United Kingdom; Dr Caroline A.
 526 Mitchell, University of Sheffield, United Kingdom; Joanne C. Mockler, Monash University and
 527 Monash Health, Australia; Sally-Ann Molsher, United Lincolnshire Hospitals NHS Trust,
 528 United Kingdom; Elizabeth S. Monast, United States; Professor Emeritus Jagidesa Moodley,
 529 University of Kwa Zulu-Natal, South Africa; Dr Rob Mooij, Beatrix Hospital, The Netherlands;
 530 Emma L. Moore, United Kingdom; Dr Linda Morgan, University of Nottingham, United
 531 Kingdom; Dr Angela Moulson, United Kingdom; Dr Faraz Mughal, Keele University, United
 532 Kingdom; Dr Shuchita R. Mundle, Government Medical College, Nagpur, India; Dr Miguel
 533 Angel Munoz, Institut Catala de la Salut. IdiapJgol, Spain; Professor Elizabeth Murray,
 534 University College London, United Kingdom; Dr Chie Nagata, National Center for Child
 535 Health and Development, Japan; Dr Abhijit S. Nair, Basavatarakam Indo-American Cancer
 536 Hospital and Research Institute, India; Professor Annettee Nakimuli, Uganda; Dr Gita Nath,
 537 Axon Anaesthesia Associates, India; Rachel S. Newport, Pennine Acute Hospitals NHS
 538 Trust, United Kingdom; Professor Pippa Oakeshott, St George's, University of London,
 539 United Kingdom; Dr Maria R. Ochoa-Ferraro, Norfolk and Norwich University Hospital,
 540 United Kingdom; Professor Hein Odendaal, Stellenbosch University, South Africa; Professor
 541 Akihide Ohkuchi, Jichi Medical University School of Medicine, Japan; Professor Leandro
 542 Oliveira, São Paulo State University, Brazil; Dr Eduardo Ortiz-Panozo, National Institute of
 543 Public Health, Mexico; Dr Martijn A. Oudijk, Amsterdam Universitair Medische Centra, The
 544 Netherlands; Dr Seyhan E. Oygucu, University of Kyrenia, Turkey; Emeritus Professor

545 Michael J. Paech, King Edward Memorial Hospital, Australia; Dr Rebecca C. Painter,
 546 Amsterdam University Centres, The Netherlands; Claire L. Parry, United Kingdom; Dr Beth
 547 A. Payne, University of British Columbia, Canada; Emma L. Pearson, United Kingdom;
 548 Professor Vorapong Phupong, Chulalongkorn University, Thailand; Naomi Pickett, United
 549 Kingdom; Katie A. Pickles, United Kingdom; Louise K. Plumb, United Kingdom; Dr Federico
 550 Prefumo, University of Brescia, Italy; Professor Roanne Preston, University Of British
 551 Columbia, Canada; Dr Joel G. Ray, University of Toronto, Canada; Dr Juliet Rayment,
 552 United Kingdom; Lynsey V. Regan, United Kingdom; Dr Evelyne Rey, University of Montreal,
 553 Canada; Dr Emily J. Robson, United Kingdom; Antonia N. Rubin, United Kingdom; Professor
 554 Jorge A. Rubio-Romero, Universidad Nacional de Colombia, Colombia; Dr Kristiina Rull,
 555 Women's Clinic of Tartu University Hospital, Estonia; Professor Nelson Sass, Universidade
 556 Federal de São Paulo, Brazil; Professor Nadine Sauvé, Université de Sherbrooke, Canada;
 557 Nicola A. Savory, University Hospital of Wales, United Kingdom; Professor James R. Scott,
 558 University of Iowa, United States; Dr Sarah E. Seaton, University of Leicester, United
 559 Kingdom; Paul T. Seed, King's College London, United Kingdom; Dr Judy M. Shakespeare,
 560 United Kingdom; Dr Antonia W. Shand, University of Sydney, Australia; Dr Sanjay Sharma,
 561 Westmead Hospital, Australia; Dr Tammy Y. Shaw, Canada; Dr Kate L. Smedley, United
 562 Kingdom; Dr Drew Smith, Princess Royal Maternity, United Kingdom; Ashley Smith Conk,
 563 United States; Donna Soward, Australia; Professor Holger Stepan, Leipzig University,
 564 Germany; Dr Konstantinos Stroumpoulis, Centre Hospitalier Public du Cotentin, France; Dr
 565 Anoop Surendran, Lewisham and Greenwich NHS Trust, United Kingdom; Professor Satoru
 566 Takeda, Juntendo University Faculty of Medicine, Japan; Dr Lawrence Tan, Western Sydney
 567 University, Australia; Becky S. Theriot, United States; Hayley F. Thomas, Netherlands;
 568 Karen Thompson, Australia; Dr Peter I. Thompson, National Institute of Health Research,
 569 United Kingdom; Professor Matthew J. Thompson, University of Washington, United States;
 570 Laura Toms, United Kingdom; Kate L. H. T. Torney, United Kingdom; Dr Julian S. Treadwell,
 571 University of Oxford, United Kingdom; Dr Katherine L. Tucker, University of Oxford, United
 572 Kingdom; Dr Mark A. Turrentine, Baylor College of Medicine, United States; Dr Oliver Van

Hecke, University of Oxford, United Kingdom; Dr Miriam F. Van Oostwaard, Capelle aan den IJssel, The Netherlands; Dr Daniela N. Vasquez, Sanatorio Anchorena, Argentina; Dr David J. A. Vaughan, London North West University Healthcare NHS Trust, United Kingdom; Dr Angela VInturache, Oxford University Hospitals NHS Foundation Trust, United Kingdom; Professor James Walker, University of Leeds, United Kingdom; Dr Stephen P. Wardle, Nottingham University Hospitals NHS Trust, United Kingdom; Professor Tayyiba Wasim, Institute of Medical Sciences, Lahore, Pakistan; Dr Jonathan H. Waters, UPMC Magee Womens Hospital, United States; Dr Clare L. Whitehead, University of Toronto, Canada; Dr Alexander Wolfson, Penn Medicine Princeton Health, United States; Professor Seonae Yeo, University of North Carolina at Chapel Hill, United States; and Dr Arnold G. Zernansky, University of Leeds, United Kingdom.

Acknowledgments

This paper reports independent research arising from a doctoral fellowship (DRF-2014-07-051) supported by the National Institute for Health Research. The study was also supported by funding from the Barts Charity and Elizabeth Garrett Anderson Hospital Charity. Dr Chris Gale was supported by a Medical Research Council Clinician Scientist Fellowship. Prof Richard McManus was supported by a National Institute for Health Research Professorship (NIHR-RP-R2-12-015) and the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care Oxford. Prof Mol is supported by a National Health and Medical Research Practitioner Fellowship (GNT1082548). Prof Richard McManus, Prof Paula Williamson, and Prof Sue Ziebland are supported by National Institute for Health Research Senior Investigator awards. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.

We would like to thank the healthcare professionals and researchers who participated in the consensus development meeting. We would like to thank the Radcliffe Women's Health

Patient Participation group, Action on Pre-eclampsia, and our patient and public representatives who assisted with study design, data interpretation, and planned dissemination. We would like to thank colleagues at the Nuffield Department of Primary Care Health Sciences, University of Oxford including Jacqui Belcher, Carla Betts, Lucy Curtin, Dawn Evans, Caroline Jordan, Sarah King, Sam Monaghan, Dan Richards-Doran, Nicola Small, and Clare Wickings for administrative, technical, or material support. We would like to thank Prof. Marian Knight, Nuffield Department of Population Health, University of Oxford, for providing subject-specific expertise. We would like to thank colleagues at the Women's Health Research Unit, Queen Mary, University of London including Khalid Khan, Tracy Holtham, and Rehan Khan for administrative, technical support, or subject-specific expertise.

References

- [1] J.M.N. Duffy, M. Hirsch, A. Kawsar, C. Gale, L. Pealing, M.N. Plana, M. Showell, P.R. Williamson, K.S. Khan, S. Ziebland, R.J. McManus, Outcome reporting across randomised controlled trials evaluating therapeutic interventions for pre-eclampsia, *BJOG* 124(12) (2017) 1829-1839.
- [2] J.M.N. Duffy, M. Hirsch, C. Gale, L. Pealing, A. Kawsar, M. Showell, P.R. Williamson, K.S. Khan, S. Ziebland, R.J. McManus, A systematic review of primary outcome and outcome measure reporting in randomized trials evaluating treatments for preeclampsia, *Int J Gynecol Obstet* 139(3) (2017) 262-267.
- [3] J.M.N. Duffy, M. Hirsch, L. Pealing, M. Showell, K.S. Khan, S. Ziebland, R.J. McManus, Inadequate safety reporting in pre-eclampsia trials: A systematic evaluation, *BJOG* 125(7) (2018) 795-803.
- [4] M. Hirsch, J.M.N. Duffy, J.O. Kuszniir, C.J. Davis, M.N. Plana, K.S. Khan, Variation in outcome reporting in endometriosis trials: a systematic review, *Am J Obstet Gynecol* 214(4) (2016) 452-464.
- [5] F.G. Sileo, J.M.N. Duffy, R. Townsend, A. Khalil, Variation in outcome reporting across studies evaluating interventions for selective fetal growth restriction, *Ultrasound Obstet Gynecol* 54(1) (2019) 10-15.
- [6] J.W.H. Webbe, S. Ali, S. Sakonidou, T. Webbe, J.M.N. Duffy, G. Brunton, N. Modi, C. Gale, Inconsistent outcome reporting in large neonatal trials: a systematic review, *Arch Dis Child* 105(1) (2020) 69-75.

- [7] J. Duffy, S. Bhattacharya, M. Herman, B. Mol, A. Vail, J. Wilkinson, C. Farquhar, Reducing research waste in benign gynaecology and fertility research, *BJOG* 124(3) (2017) 366-369.
- [8] J.M.N. Duffy, J. van 't Hooft, C. Gale, M. Brown, W. Grobman, R. Fitzpatrick, S. Karumanchi, N. Lucas, L. Magee, B. Mol, M. Stark, S. Thangaratinam, M. Wilson, P. von Dadelszen, P. Williamson, K. Khan, S. Ziebland, R. McManus, A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia, *Pregnancy Hypertens* 6(4) (2016) 274-278.
- [9] P.R. Williamson, D.G. Altman, H. Bagley, K.L. Barnes, J.M. Blazeby, S.T. Brookes, M. Clarke, E. Gargon, S. Gorst, N. Harman, J.J. Kirkham, A. McNair, C.A.C. Prinsen, J. Schmitt, C.B. Terwee, B. Young, The COMET Handbook: version 1.0, *Trials* 18(3) (2017) 280.
- [10] J.M.N. Duffy, T. Thompson, L. Hinton, M. Salinas, R.J. McManus, S. Ziebland, What outcomes should researchers select, collect and report in pre-eclampsia research? A qualitative study exploring the views of women with lived experience of pre-eclampsia, *BJOG* 126(5) (2019) 637-646.
- [11] J.M.N. Duffy, M. Hirsch, S. Ziebland, R.J. McManus, Methodological decisions influence the identification of potential core outcomes in studies related to pre-eclampsia: an analysis informing the development of recommendations for future core outcome set developers, *BJOG* 126(12) (2019) 1482-1490.
- [12] J.M.N. Duffy, R. Rolph, C. Gale, M. Hirsch, K.S. Khan, S. Ziebland, R.J. McManus, Core outcome sets in women's and newborn health: A systematic review, *BJOG* 124(10) (2017) 1481-1489.
- [13] F.T. Da Silva, B. Gonik, M. McMillan, C. Keech, S. Dellicour, S. Bhange, M. Tila, D.M. Harper, C. Woods, A.T. Kawai, S. Kochhar, F.M. Munoz, Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data, *Vaccine* 34(49) (2016) 6057-6068.
- [14] J.M.N. Duffy, S. Ziebland, P. von Dadelszen, R.J. McManus, Tackling poorly selected, collected, and reported outcomes in obstetrics and gynecology research, *Am J Obstet Gynecol* 220(1) (2019) 71.e1-71.e4.
- [15] M. Hirsch, J.M.N. Duffy, C. Barker, L. Hummelshoj, N.P. Johnson, B. Mol, K.S. Khan, C. Farquhar, Protocol for developing, disseminating and implementing a core outcome set for endometriosis, *BMJ Open* 6(12) (2016) e013998.
- [16] J.M.N. Duffy, M. Hirsch, M. Vercoe, J. Abbott, C. Barker, B. Collura, R. Drake, J. Evers, M. Hickey, A.W. Horne, M.L. Hull, S. Kolekar, S. Lensen, N.P. Johnson, V. Mahajan, B.W. Mol, A.S. Otter, L. Puscasiu, M.B. Rodriguez, L. Rombauts, A. Vail, R. Wang, C.M. Farquhar, A core outcome set for future endometriosis research: an international consensus development study, *BJOG* (2020) DOI: 10.1111/1471-0528.16157.

- 670 [17] J.W.H. Webbe, J.M.N. Duffy, E. Afonso, I. Al-Muzaffar, G. Brunton, A. Greenough, N.J.
671 Hall, M. Knight, J.M. Latour, C. Lee-Davey, N. Marlow, L. Noakes, J. Nycyk, A. Richard-
672 Löndt, B. Wills-Eve, N. Modi, C. Gale, Core outcomes in neonatology: development of a core
673 outcome set for neonatal research, *Arch Dis Child* (2019) 10.1136/archdischild-2019-
674 317501.
- 675 [18] J.W.H. Webbe, J.M.N. Duffy, E. Afonso, I. Al-Muzaffar, G. Brunton, A. Greenough, N.J.
676 Hall, M. Knight, J.M. Latour, C. Lee-Davey, N. Marlow, L. Noakes, J. Nycyk, A. Richard-
677 Löndt, B. Wills-Eve, N. Modi, C. Gale, Core outcomes in neonatology: development of a core
678 outcome set for neonatal research, *Archives of Disease in Childhood - Fetal and Neonatal*
679 *Edition* (2019) fetalneonatal-2019-317501.
- 680 [19] K.C. Whitehouse, C.R. Kim, B. Ganatra, J.M.N. Duffy, J. Blum, D. Brahmi, M.D. Creinin,
681 T. DePiñeres, K. Gemzell-Danielsson, D. Grossman, B. Winikoff, A.M. Gülmezoglu,
682 Standardizing abortion research outcomes (STAR): a protocol for developing, disseminating
683 and implementing a core outcome set for medical and surgical abortion, *Contraception* 95(5)
684 (2017) 437-441.
- 685 [20] A. Khalil, H. Perry, J.M.N. Duffy, K. Reed, A. Baschat, J. Deprest, K. Hecher, L. Lewi, E.
686 Lopriore, D. Oepkes, Twin-Twin Transfusion Syndrome: study protocol for developing,
687 disseminating, and implementing a core outcome set, *Trials* 18(1) (2017) 325.
- 688 [21] H. Perry, J.M.N. Duffy, K. Reed, A. Baschat, J. Deprest, K. Hecher, L. Lewi, E. Lopriore,
689 D. Oepkes, A. Khalil, Core outcome set for research studies evaluating treatments for twin-
690 twin transfusion syndrome, *Ultrasound Obstet Gynecol* 54(2) (2019) 255-261.
- 691 [22] M.A. Nijagal, S. Wissig, C. Stowell, E. Olson, I. Amer-Wahlin, G. Bonsel, A. Brooks, M.
692 Coleman, S. Devi Karalasingam, J.M.N. Duffy, T. Flanagan, S. Gebhardt, M.E. Greene, F.
693 Groenendaal, J.R. R Jeganathan, T. Kowaliw, M. Lamain-de-Ruiter, E. Main, M. Owens, R.
694 Petersen, I. Reiss, C. Sakala, A.M. Speciale, R. Thompson, O. Okunade, A. Franx,
695 Standardized outcome measures for pregnancy and childbirth, an ICHOM proposal, *BMC*
696 *Health Services Research* 18(1) (2018) 953.
- 697 [23] J.M.N. Duffy, S. Bhattacharya, C. Curtis, J.L.H. Evers, R.G. Farquharson, S. Franik, Y.
698 Khalaf, R.S. Legro, S. Lensen, B.W. Mol, C. Niederberger, E.H.Y. Ng, S. Repping, A.
699 Strandell, H.L. Torrance, A. Vail, M. van Wely, N.L. Vuong, A.Y. Wang, R. Wang, J.
700 Wilkinson, M.A. Youssef, C.M. Farquhar, A protocol developing, disseminating and
701 implementing a core outcome set for infertility, *Hum Reprod Open*, 2018, p. hoy007.
- 702 [24] A. Khalil, J.M.N. Duffy, H. Perry, W. Ganzevoort, K. Reed, A.A. Baschat, J. Deprest, E.
703 Gratacos, K. Hecher, L. Lewi, E. Lopriore, D. Oepkes, A. Papageorgiou, S.J. Gordijn, Study
704 protocol: developing, disseminating, and implementing a core outcome set for selective fetal
705 growth restriction in monochorionic twin pregnancies, *Trials* 20(1) (2019) 35.

- [25] R. Townsend, J.M.N. Duffy, F. Sileo, H. Perry, W. Ganzevoort, K. Reed, A.A. Baschat, J. Deprest, E. Gratacos, K. Hecher, L. Lewi, E. Lopriore, D. Oepkes, A. Papageorgiou, S.J. Gordijn, A. Khalil, Core outcome set for studies investigating management of selective fetal growth restriction in twins, *Ultrasound Obstet Gynecol* 55(5) (2020) 652-660.
- [26] L. Jansen, M. Koot, J. van't Hooft, C. Dean, J. Duffy, W. Ganzevoort, N. Gauw, B. Goes, J. Rodenburg, T. Roseboom, R. Painter, I. Grooten, A core outcome set for hyperemesis gravidarum research: An international consensus study, *BJOG* (2020) 10.1111/1471-0528.16172.
- [27] T.E. Gillon, A. Pels, P. von Dadelszen, K. MacDonell, L.A. Magee, Hypertensive disorders of pregnancy: A systematic review of international clinical practice guidelines, *PLOS One* 9(12) (2014) e113715.
- [28] J.M.N. Duffy, A.E. Cairns, D. Richards-Doran, J. van 't Hooft, C. Gale, M. Brown, W. Grobman, R. Fitzpatrick, S.A. Karumanchi, N. Lucas, L. Magee, B. Mol, M. Stark, S. Thangaratinam, M. Wilson, P. von Dadelszen, P. Williamson, S. Ziebland, R.J. McManus, A core outcome set for pre-eclampsia research: An international consensus development study, *BJOG* (2020) DOI: 10.1111/1471-0528.16319.
- [29] M. Murphy, C. Sanderson, N. Black, J. Askham, D. Lamping, T. Marteau, C. McKee Consensus development methods, and their use in clinical guideline development, *Health Technol Assess* 2(3) (1998) 1-88.
- [30] M.A. Brown, L.A. Magee, L.C. Kenny, S.A. Karumanchi, F.P. McCarthy, S. Saito, D.R. Hall, C.E. Warren, G. Adoyi, S. Ishaku, Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice, *Hypertension* 72(1) (2018) 24-43.
- [31] L. Myatt, C.W. Redman, A.C. Staff, S. Hansson, M.L. Wilson, H. Laivuori, L. Poston, J.M. Roberts, Strategy for standardization of preeclampsia research study design, *Hypertension* 63(6) (2014) 1293-301.
- [32] L. Hoj, D. Da Silva, K. Hedegaard, A. Sandstrom, P. Aaby, Maternal mortality: Only 42 days?, *BJOG* 110(11) (2003) 995-1000.
- [33] C. Bushnell, M. Chireau, Preeclampsia and stroke: Risks during and after pregnancy, *Stroke Res Treat* 1 (2011) 1-9.
- [34] World Health Organization, International statistical classification of diseases and related health problems, World Health Organization, Geneva, Switzerland, 2004.
- [35] S. Ftouh, M. Thomas, Acute kidney injury: Summary of NICE guidance, *BMJ* 347 (2013) f4930.
- [36] R. Bellomo, C. Ronco, J.A. Kellum, R.L. Mehta, P. Palevsky, A.w. the, Acute renal failure – definition, outcome measures, animal models, fluid therapy and information

- 742 technology needs: the Second International Consensus Conference of the Acute Dialysis
743 Quality Initiative (ADQI) Group, *Crit Care Med* 8(4) (2004) 204-212.
- 744 [37] R.L. Mehta, J.A. Kellum, S.V. Shah, B.A. Molitoris, C. Ronco, D.G. Warnock, A. Levin,
745 Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney
746 injury, *Crit Care Med* 11(2) (2007) R31.
- 747 [38] A. Khwaja, Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice
748 guidelines for acute kidney injury, *Nephron Clin Pract* 120(4) (2012) c179-84.
- 749 [39] G. Carroli, J. Villar, G. Piaggio, D. Khan-Neelofur, M. Gülmezoglu, M. Mugford, P.
750 Lumbiganon, U. Farnot, P. Bersgjø, WHO systematic review of randomised controlled trials
751 of routine antenatal care, *Lancet* 357(9268) (2001) 1565-1570.
- 752 [40] P. von Dadelszen, B. Payne, J. Li, J.M. Ansermino, F.B. Pipkin, A.-M. Côté, M.J.
753 Douglas, A. Gruslin, J.A. Hutcheon, K.S. Joseph, P.M. Kyle, T. Lee, P. Loughna, J.M.
754 Menzies, M. Merialdi, A.L. Millman, M.P. Moore, J.-M. Moutquin, A.B. Ouellet, G.N. Smith,
755 J.J. Walker, K.R. Walley, B.N. Walters, M. Widmer, S.K. Lee, J.A. Russell, L.A. Magee,
756 Prediction of adverse maternal outcomes in pre-eclampsia: Development and validation of
757 the fullPIERS model, *Lancet* 377(9761) (2011) 219-227.
- 758 [41] R. Kerr, L.O. Eckert, B. Winikoff, J. Durocher, S. Meher, S. Fawcus, S. Mundle, B. Mol,
759 S. Arulkumaran, K. Khan, J. Wandwabwa, S. Kochhar, A. Weeks, Postpartum haemorrhage:
760 Case definition and guidelines for data collection, analysis, and presentation of immunization
761 safety data, *Vaccine* 34(49) (2016) 6102-6109.
- 762 [42] T. Lertbunnaphong, N. Lapthanapat, J. Leetheeragul, P. Hakularb, A. Ownon,
763 Postpartum blood loss: Visual estimation versus objective quantification with a novel birthing
764 drape, *Singapore Med J* 57(6) (2016) 325-328.
- 765 [43] T. Glanville, J. Walker, HELLP syndrome, *Obstet Gynaecol* 5(3) (2003) 149-154.
- 766 [44] S. Elatrous, S. Nouria, L. Ouanes Besbes, S. Marghli, M. Boussarssar, M. Sakkouhi, F.
767 Abroug, Short-term treatment of severe hypertension of pregnancy: prospective comparison
768 of nifedipine and labetalol, *Intensive Care Med* 28(9) (2002) 1281-6.
- 769 [45] S. Murthy, A. Leligdowicz, N.K.J. Adhikari, Intensive care unit capacity in low-income
770 countries: A systematic review, *PLOS One* 10(1) (2015) e0116949.
- 771 [46] D. Dutta, M. Sule, A. Ray, Epidural therapy for the treatment of severe pre-eclampsia in
772 non labouring women, *Cochrane Database Syst Rev* 1 (2012) CD009540.
- 773 [47] C.E. Rubens, M.G. Gravett, C.G. Victora, T.M. Nunes, Global report on preterm birth
774 and stillbirth: mobilizing resources to accelerate innovative solutions, *BMC Pregnancy Childb*
775 10(1) (2010) S7.
- 776 [48] E.P. Schlaudecker, F.M. Munoz, A. Bardají, N.S. Boghossian, A. Khalil, H. Mousa, M.
777 Nesin, M.I. Nisar, V. Pool, H.M.L. Spiegel, M.D. Tapia, S. Kochhar, S. Black, Small for

gestational age: Case definition and guidelines for data collection, analysis, and presentation
of maternal immunisation safety data, *Vaccine* 35(48) (2017) 6518-6528.

[49] J. Gardosi, A. Francis, S. Turner, M. Williams, Customized growth charts: Rationale, validation and clinical benefits, *Am J Obstet Gynecol* 218(2) (2018) S609-18.

[50] World Health Organization, Guidelines on neonatal seizures, World Health Organization, Geneva, Switzerland, 2011.

[51] E. Bancalari, N. Claure, Advances in respiratory support for high risk newborn infants, *Matern Neonatol Perinatol* 1 (2015) 13.

[52] AAP Committee on Fetus and Newborn, Guidelines for Perinatal Care, American Academy of Pediatrics, Washington, United States, 2017.

[53] S.G. Moxon, J.E. Lawn, K.E. Dickson, A. Simen-Kapeu, G. Gupta, A. Deorari, N. Singhal, K. New, C. Kenner, V. Bhutani, R. Kumar, E. Molyneux, H. Blencowe, Inpatient care of small and sick newborns: A multi-country analysis of health system bottlenecks and potential solutions, *BMC Pregnancy Childb* 15(2) (2015) S7.

[54] M.A. Demitrack, D. Faries, J.M. Herrera, D. DeBrotta, W.Z. Potter, The problem of measurement error in multisite clinical trials, *Psychopharmacol Bulletin* 34(1) (1998) 19-24.

[55] A. Hrobjartsson, A.S. Thomsen, F. Emanuelsson, B. Tendal, J. Hilden, I. Boutron, P. Ravaut, S. Brorson, Observer bias in randomised clinical trials with binary outcomes: Systematic review of trials with both blinded and non-blinded outcome assessors, *BMJ* 344 (2012) e1119.

[56] S. Kochhar, J. Bonhoeffer, C.E. Jones, F.M. Munoz, A. Honrado, J. Bauwens, A. Sobanjo-Ter Meulen, S. Hirschfeld, Immunization in pregnancy clinical research in low- and middle-income countries: Study design, regulatory and safety considerations, *Vaccine* 35(48) (2017) 6575-6581.

[57] A.J. Devall, H.J. Out, B.W.J. Mol, J.M.N. Duffy, B. Collura, S. Dyer, Coordination and planning of clinical research on a national and global level, *Fertility and Sterility* 113(6) (2020) 1100-1106.

[58] L. Graham, B. Illingworth, M. Showell, M. Vercoe, E. Crosbie, L. Gingel, C. Farquhar, A. Horne, M. Prior, J. Stephenson, L. Magee, J.M.N. Duffy, Research priority setting in women's health: a systematic review, *BJOG* 127(6) (2020) 694-700.

[59] R. Townsend, J.M.N. Duffy, A. Khalil, Increasing value and reducing research waste in obstetrics: towards woman-centered research, *Ultrasound Obstet Gynecol* 55(2) (2020) 151-156.

[60] A.J. Poprzeczny, K. Stocking, M. Showell, J.M.N. Duffy, Patient Decision Aids to Facilitate Shared Decision Making in Obstetrics and Gynecology: A Systematic Review and Meta-analysis, *Obstet Gynecol* 135(2) (2020) 444-451.

